Do you want to read an article? Please log in or register.
Treat-and-Extend versus Monthly Regimen in Neovascular Age-Related Macular Degeneration: Results with Ranibizumab from the TREND Study
Macular Diseases
Related content
COMMENTED
Macular Diseases
Tolerating Subretinal Fluid in Neovascular Age-Related Macular Degeneration Treated With Ranibizumab Using a Treat and Extend Regimen: FLUID Study 24 Month Results
Ophthalmology.
Guymer RH, Markey CM, McAllister IL, Gillies MC, Hunyor AP, Arnold JJ; FLUID Investigators
doi: 10.1016/j.ophtha.2018.11.025.
COMMENTED
Macular Diseases
Canadian Treat and Extend Analysis Trial with Ranibizumab in Patients with Neovascular Age-related Macular Disease: 1-Year Results of the Randomized CANTREAT Study
Ophthalmology.
Kertes PJ, Galic IJ, Greve M, Williams RG, Rampakakis E, Scarino A, Sheidow T
doi: 10.1016/j.ophtha.
COMMENTED
Macular Diseases
Efficacy of a Treat-and-Extend Regimen With Ranibizumab in Patients With Neovascular Age-Related Macular Disease: A Randomized Clinical Trial
★ 3
Recommended by
Prof. Dr Daniel Barthelmes, Faculty Member
★ 3
Recommended and commented by
Prof. Dr Stephan Michels, Faculty Member
JAMA Ophthalmol.
Kertes PJ, Galic IJ, Greve M, Williams G, Baker J, Lahaie M, Sheidow T
doi: 10.1001/jamaophthalmol.2019.5540.
COMMENTED
Macular Diseases
Effect of Ranibizumab and Aflibercept on Best-Corrected Visual Acuity in Treat-and-Extend for Neovascular Age-Related Macular Degeneration: A Randomized Clinical Trial
JAMA Ophthalmol.
Gillies MC, Hunyor AP, Arnold JJ, Guymer RH, Wolf S, Ng P, Pecheur FL, McAllister IL
doi: 10.1001/jamaophthalmol.
Macular Diseases
Effect of posterior vitreous detachment on treat-and-extend versus monthly ranibizumab for neovascular age-related macular degeneration
Br J Ophthalmol.
Waldstein SM, Coulibaly L, Riedl S, Sadeghipour A, Gerendas BS, Schmidt-Erfurth UM
doi: 10.1136/bjophthalmol-2019-314661.
Macular DiseasesRetinal Diseases
The treat-and-extend injection regimen versus alternate dosing strategies in age-related macular degeneration: a systematic review and meta-analysis
Am J Ophthalmol.
Okada M, Kandasamy R, Chong EW, McGuiness M, Guymer RH
doi: 10.1016/j.ajo.2018.05.026.
Macular Diseases
Role of intraretinal and subretinal fluid on clinical and anatomical outcomes in patients with neovascular age-related macular degeneration treated with bimonthly, treat-and-extend and as-needed ranibizumab in the In-Eye study
Acta Ophthalmol
Saenz-de-Viteri M, Recalde S, Fernandez-Robredo P, López Gálvez MI, Arias Barquet L, Figueroa MS, García-Arumí J, García-Layana A, In-Eye Study Group.
doi: 10.1111/aos.14786
Macular Diseases
Treat-and-extend versus fixed bimonthly treatment regimens for treatment-naive neovascular age-related macular degeneration: real world data from the Fight Retinal Blindness registry
Graefes Arch Clin Exp Ophthalmol
Figueras-Roca M, Parrado-Carrillo A, Nguyen V, Casaroli-Marano RP, Moll-Udina A, Gillies MC, Barthelmes D, Zarranz-Ventura J
doi: 10.1007/s00417-020-05016-9
Cornea and Corneal DiseasesConjunctivitisBlindness and Vision ImpairmentFlammer SyndromeGlaucoma and Ocular PressureLensesMacular DiseasesOcular OncologyRetinal DiseasesSurgery and InterventionUveitisCataractsDry Eye Disease
Two different treatment regimens of ranibizumab 0.5 mg for neovascular age-related macular degeneration with or without polypoidal choroidal vasculopathy in Chinese patients: results from the Phase IV, randomized, DRAGON study
Acta Ophthalmol
Li X, Zhu Q, Egger A, Chang L, Wolf S, Song Y, Zhang J, Dong F, Xu X, Weisberger A
doi: 10.1111/aos.14588